CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Treprostinil sodium

Last Updated: February 24, 2006
Result type: Reports
Project Number: S0052
Product Line: Reimbursement Review

Generic Name: Treprostinil sodium

Brand Name: Remodulin

Manufacturer: Northern Therapeutics Inc.

Indications: Pulmonary arterial hypertension (NYHA Class III and IV patients)

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: July 20, 2006

Recommendation Type: List with clinical criteria and/or conditions